Skip to main content
Clinical Trials/NCT03356366
NCT03356366
Active, Not Recruiting
N/A

Magnetic Resonance Imaging Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis

Assistance Publique Hopitaux De Marseille1 site in 1 country70 target enrollmentOctober 2, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
70
Locations
1
Primary Endpoint
Measurement of the Expanded Disability Status Scale (EDSS) value (score from 0 to 20) constituing the actual international reference scale to measure the level of disability caused by parkinson disease
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

Multiple sclerosis (MS) is the first non-traumatic cause of disability in young people, responsible for physical but also cognitive deficits. MS is an inflammatory demyelinating and degenerative disease of the central nervous system. Recently, MRI technics have demonstrated their sensibility to the different processes involved in MS. Particularly, MRI has evidenced that the pathological process of MS is not restricted to the macroscopic lesions of the white matter but also involves the normal appearing white and grey matter. In the normal appearing brain tissue, demyelination, neuronal suffering and neuronal loss have been evidenced. Moreover, MRI has demonstrated the existence of brain functional reorganization processes that may limit the clinical expression of pathological injuries. Despite these important findings, the pathological underpinnings of irreversible disability are largely unknown. The present project aims to depict the main determinants of physical but also cognitive disability in patients with MS. To do this, a longitudinal study including 70 patients with MS using different MRI markers known to be sensitive to the different pathological aspects of MS will be performed. The relationships between these markers and the progression of disability will be assessed. Identification of the main pathological underpinnings of irreversible disability of MS will provide the most relevant therapeutic targets.

Registry
clinicaltrials.gov
Start Date
October 2, 2017
End Date
December 31, 2028
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Major patient,
  • Patient affiliated to a health insurance plan
  • Patient having signed free and informed consent after receiving detailed, understandable and honest information,
  • Patient with multiple sclerosis according to the criteria of Polman 2010

Exclusion Criteria

  • Patients with the usual contraindications to MRI (pace-maker, agitation, metal splinters, claustrophobia etc.)
  • Patients at risk of non-compliance on examination: impaired understanding, confusion, involuntary movements, poor tolerance of prolonged supine
  • Patients with known allergy to gadolinium
  • Patients with renal insufficiency
  • Patients unable to give their consent: disorders of the comprehension, disturbances of vigilance, confusion ...
  • Pregnant and breastfeeding woman
  • Patients with a history of neurological or psychiatric pathology
  • Patients under guardianship or curatorship

Outcomes

Primary Outcomes

Measurement of the Expanded Disability Status Scale (EDSS) value (score from 0 to 20) constituing the actual international reference scale to measure the level of disability caused by parkinson disease

Time Frame: 5 years

Study Sites (1)

Loading locations...

Similar Trials